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Abstract  
Introduction: Sarcoidosis is a chronic granulomatous disease of unknown aetiology with a variable 
clinical course and prognosis. There is a growing need to identify non-invasive biomarkers to 
differentiate between clinical phenotypes, identify those at risk of disease progression and monitor 
response to treatment.  
Objectives: We undertook a systematic review and meta-analysis to evaluate the utility of breath-
based biomarkers in discriminating sarcoidosis from healthy controls, alongside correlation with 
existing non breath-based biomarkers used in clinical practice, radiological stage, markers of disease 
activity and response to treatment.  
Methods: Electronic searches were undertaken during November 2017 using PubMed, Ebsco, Embase 
and Web of Science to capture relevant studies evaluating breath-based biomarkers in adult patients 
with sarcoidosis.  
Results: 353 papers were screened; 21 met the inclusion criteria and assessed 25 different biomarkers 
alongside VOCs in exhaled breath gas or condensate. Considerable heterogeneity existed amongst the 
studies in terms of participant characteristics, sampling and analytical methods. Elevated biomarkers 
in sarcoidosis included 8-isoprostane, carbon monoxide, neopterin, TGF-β1, TNFα, CysLT and several 
metallic elements including chromium, silicon and nickel. Three studies exploring VOCs were able to 
distinguish sarcoidosis from controls. Meta-analysis of four studies assessing alveolar nitric oxide 
showed no significant difference between sarcoidosis and healthy controls (2.22ppb; 95% CI -0.83, 
5.27) however, a high degree of heterogeneity was observed with an I2 of 93.4% (p<0.001). 
Inconsistent or statistically insignificant results were observed for correlations between several 
biomarkers and radiological stage, markers of disease activity or treatment.  
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Conclusions: The evidence for using breath biomarkers to diagnose and monitor sarcoidosis remains 
inconclusive with many studies limited by small sample sizes and lack of standardisation. VOCs have 
shown promising potential but further research is required to evaluate their prognostic role. 
Background 
Sarcoidosis is a chronic multi-system disease of unknown aetiology characterised by the presence of 
non-caseating epithelioid cell granulomas (1). Almost any organ can be affected with involvement of 
the lung parenchyma and intrathoracic lymph nodes occurring in 90% of patients (2). The exact 
aetiology remains inconclusive and is likely to involve both genetic and environmental factors resulting 
in an exaggerated immune response to an unidentified antigen (3). Infective agents such as 
mycobacterium and Propionibacterium acnes have been postulated as possible precipitating antigens 
(4). 
The clinical course and prognosis of sarcoidosis is extremely variable with spontaneous remission 
occurring in up to 50% of patients within 2 years of diagnosis and in the vast majority of cases within 
5 years (3). Up to a third may develop a chronic and progressive disease (1), resulting in increased 
morbidity or mortality due to pulmonary fibrosis, cardiac or neurological involvement. Current 
treatment strategies focus around immunosuppression with corticosteroids, however, the evidence 
for this remains weak (5). In addition, such treatment is often prolonged and may give rise to 
significant side effects. 
Currently there is a distinct lack of clinically useful and robust biomarkers with sufficient sensitivity 
and specificity to help aid diagnosis, predict patterns of clinical behaviour, determine prognosis or 
monitor response to treatment. Decisions to commence treatment in those with pulmonary disease 
are often challenging and frequently based upon clinical symptoms or pulmonary function tests alone. 
Various biomarkers have been assessed in urine, serum and bronchoalveolar lavage fluid but lack 
adequate sensitivity and specificity for clinical use (6). Many are not routinely available in clinical 
practice or require invasive sampling methods and are therefore unsuitable for serial monitoring.  
Page 3 of 47 AUTHOR SUBMITTED MANUSCRIPT - JBR-100911.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
nu
scr
ipt
4 
 
There is a growing need to develop non-invasive biomarkers which not only aid in diagnosis, but also 
measure disease activity and guide treatment decisions particularly as medicine evolves and becomes 
more personalised to the individual patient. Collecting and analysing components in exhaled breath is 
one such method (7) and may involve analysing either exhaled gas or breath condensate (8).  
A wide range of potential biomarkers in exhaled breath have been assessed in sarcoidosis including 
nitric oxide, eicosanoids, inflammatory cytokines, markers of granulomatous inflammation and 
volatile organic compounds (VOCs). To date no previous systematic review has been performed to 
evaluate the current evidence of such markers and their use in sarcoidosis. The purpose of this 
systematic review was to examine the available evidence for the role of breath-based biomarkers and 
their utility in the diagnosis and management of sarcoidosis patients. 
Methods  
Study Design 
This systematic review was performed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analysis (PRISMA) statement (9) and was registered with the 
International Prospective Register of Systematic Reviews (PROSPERO) (Registration number: 
CRD42017076233). There were three main objectives for this systematic review which included 1) 
identification of a breath-based biomarker able to differentiate sarcoidosis from healthy controls, 2) 
differentiate between varying clinical phenotypes as well as 3) correlation with pre-existing markers 
of disease activity used in clinical practice or response to treatment.  
Search Strategy  
A literature search was performed using PubMed, Embase, Web of Science and Ebcso with the 
following search strategy: ‘sarcoidosis’ OR ‘sarcoid’ OR ‘interstitial lung disease’ OR sarcoidosis [MeSH 
Terms] AND ‘breathomics’ OR ‘exhaled breath test’ OR ‘exhaled breath’ OR ‘breath biomarker’ OR 
breath test [MeSH]. Bibliographies and reference lists were also manually screened to identify 
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additional papers. Initial electronic searches were undertaken during November 2017 and repeated 
in October 2018. No additional papers were identified during the repeated search.  
Eligibility Criteria  
The titles and abstracts of all papers identified through literature searches were reviewed and 
assessed for suitability and relevance by two independent reviewers (DT and CH). Discrepancies were 
resolved by discussion and involvement of a third reviewer (AMW). Papers considered eligible for 
inclusion were any studies that specifically evaluated any biomarker in exhaled breath in sarcoidosis 
and compared this to either healthy controls or differing clinical phenotypes (based upon radiological 
stage, pulmonary function test parameters, active vs. inactive or fibrotic vs. non-fibrotic disease). 
Other comparators of interest included treatment with immunosuppression and correlation with any 
current non breath-based biomarkers used in clinical practice and measured in either serum or 
bronchoalveolar lavage fluid. Additional inclusion criteria included 1) participants aged >18 years; 2) 
confirmation of the diagnosis of sarcoidosis as per internationally agreed standards or guidelines, 
multidisciplinary discussion or biopsy proven as well as 3) presented in full text and published in 
English. To ensure the broadest possible collection of evidence for evaluation, all study designs were 
included.  
Data Extraction and Quality Assessment  
Data extraction was performed independently by two reviewers (DT and CH) using a customised data 
collection form designed to capture the relevant information. The data collected included the main 
author’s surname, country and year of publication, number of participants and healthy controls 
including baseline characteristics such as age, gender, ethnicity, smoking status, disease activity, 
radiological stage and treatment regime if available. Additional information gathered related to the 
biomarker of interest and included sampling and analytical methods and differences in the 
concentrations reported between the two groups or comparators of interest. The quality and overall 
risk of bias was assessed using the QUADAS-2 assessment tool (10). This consists of four key domains 
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covering patient selection, index and reference tests and flow of patients through the study. For the 
purposes of this review, the index test was the breath biomarker under investigation and the 
reference standard was a diagnosis of sarcoidosis either histologically or as per internationally agreed 
criteria. Where possible, meta-analysis was performed using Open Meta Analyst (11). Where a 
particular breath biomarker was assessed in two or more studies and meta-analysis was not possible, 
a narrative review has been provided.  
Results  
Electronic searches identified a total of 353 papers, 97 of which were duplicates. Two further studies 
were identified through bibliography and reference searches. Titles and abstracts were reviewed for 
relevance and full text was retrieved for 41 studies, 21 of which met the full inclusion criteria. The 
PRISMA screening flow diagram is shown in Figure 1.  
Overall Characteristics of the Studies  
Of the 21 studies identified, three were longitudinal in design (12-14), whereas the remaining 18 were 
cross-sectional case-controlled studies. Publication dates ranged from 1997 to 2017. The sample sizes 
were relatively small across all studies and ranged from 5 to 87 participants with sarcoidosis. 
Considerable heterogeneity existed between the studies in terms of participant characteristics, 
diagnostic methods, classification of disease activity and treatment status, particularly in studies 
which assessed the same biomarker. Study characteristics are shown in Tables 1, 2 and 3.  
Alongside expired VOCs, 25 different individual breath-based biomarkers were assessed across the 
studies. Ten studies measured biomarkers in exhaled breath condensate (EBC), whereas the remaining 
eleven directly assessed biomarkers in expired breath gas. Four studies also examined the breath 
biomarker of interest in relation to the concentration in bronchoalveolar lavage fluid (BALF) and blood.  
The sampling methods also differed considerably between studies, as did the methodology for 
biomarker analysis (Table 2). EBC was sampled using a variety of collection systems and whilst all 
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studies described methodology of collection, only four cited reference to standardised 
recommendations (12) (15) (16) (17). A variety of chemiluminescence analysers were used to measure 
nitric oxide, with three studies citing sampling as per published recommendations (14, 18, 19). VOCs 
were assessed using different methods such as an electric nose, mass spectrometry, ion mobility 
spectrometry and a colorimeter sensor array.  
Utility of breath-based biomarkers in differentiating sarcoidosis from healthy controls  
Twenty studies evaluated the biomarker of interest in differentiating sarcoidosis from healthy 
controls, however, many were not adequately matched for age and gender between the two cohorts.  
Markers of oxidative stress 
Biomarkers of interest related to oxidative stress were assessed across five studies (Table 4). Four 
studies assessed 8-isoprostane in EBC; three were cross-sectional case-controlled studies and one was 
longitudinal in design (12) (16) (17) (20). In all studies 8-isoprostane was significantly higher in 
participants with sarcoidosis. The sarcoid cohorts varied between the studies with regards to disease 
duration and treatment (Table 1). Due to the heterogeneous methods of reporting it was not possible 
to pool data for meta-analysis.  
Another study assessed exhaled carbon monoxide and found that the mean concentration was 
significantly elevated in sarcoidosis compared to healthy controls (21).  
Metallic elements  
Two studies explored the concentration of metallic elements in EBC (7) (22) (Table 5). Corradi et al 
(22) evaluated various metallic elements across a variety of interstitial lung diseases, twenty-two of 
which had biopsy proven sarcoidosis. The median concentration of nickel, chromium and silicon was 
significantly higher amongst participants with sarcoidosis. Using multinomial logistic regression, 
metallic patterns in EBC could distinguish healthy controls from sarcoidosis, however overlap with 
other interstitial lung diseases occurred in 64% of cases. Mohan et al (7) reported the mean 
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concentration of calcium in EBC was significantly elevated in healthy controls compared to sarcoidosis 
patients diagnosed according to international guidelines. Similar findings were observed by Corradi et 
al with respect to calcium, however the increase failed to reach statistical significance.  
Cytokines and markers of inflammation  
Four studies assessed cytokines and markers of inflammation in EBC including cysteinyl leukotrienes 
(CysLT) (16), leukotriene B4 (LTB4) (16), tumour necrosis factor-α (TNFα) (7), neopterin (23), 
transforming growth factor-β1 (TGF-β1) (23) and interleukin-27 (IL-27) (24) (Table 5). CysLT was 
detectable in 75% (21/28) of participants with sarcoidosis and below the limit of detection in all 
controls. LTB4 was detectable in 79% (22/28) of sarcoidosis patients compared to 76% (13/17) of 
healthy controls, however, no statistically significant difference was observed between the two 
groups. TNFα was detectable in all participants, with the exception of one subject in each cohort and 
was significantly elevated in those with sarcoidosis. Neopterin was detectable in 44% (7/16) of 
participants with sarcoidosis and 10% (2/20) of healthy controls, whereas TGF-β1 was detectable in all 
subjects. Mean concentration of both neopterin and TGF-β1 was significantly higher in those with 
sarcoidosis. No statistically significant difference was observed in the mean concentration of IL-27 
between sarcoidosis and controls.  
Nitric oxide  
Exhaled nitric oxide was evaluated across six studies, four cross-sectional studies (18) (19) (25) (26) 
and two longitudinal observational studies (13) (14) involving between 10 and 52 participants (Table 
6). Studies were heterogeneous across most participant characteristics, in particular ethnicity, 
smoking status and treatment exposure which limits the comparability and generalisability. The 
analytical platform and sampling methods also differed considerably across all six studies and only 
three (14) (18) (19) carried out sampling in accordance with current available recommendations (27) 
(28).  
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Two studies measured nitric oxide at various flow rates and calculated alveolar concentration of nitric 
oxide (CAlvNO) (14) (19), whereas one study exclusively reported mean alveolar nitric oxide (13).  Of 
the remaining studies, one reported mean peak, alveolar and end-tidal nitric oxide (26), one reported 
the mean end expiratory nitric oxide (18) and the final study reported exhaled nitric oxide during the 
plateau phase of expiration when carbon dioxide was 70-80% of the maximum (25). Only two studies 
reported significantly elevated nitric oxide in participants with sarcoidosis compared to healthy 
controls which ranged from (Mean  ± SEM) 6.7 ± 0.5 versus 5.2 ± 0.73ppb p=0.05 and 9.8 ± 0.4 versus 
4.1 ± 0.2ppb p<0.001 (13) (18).   
Meta-analysis was performed on the four studies which reported alveolar nitric oxide to determine if 
alveolar nitric oxide differed between patients with sarcoidosis and healthy controls using a random 
effects model (Figure 2). When pooling data (n=95), the mean difference was 2.22ppb (CI -0.83, 5.27) 
which was statistically insignificant. The I2 test was 93.4% (p<0.001) indicating a high degree of 
heterogeneity, which most likely reflects the fact that pooled data included a mixed population 
incorporating those with active and inactive disease, alongside those with newly diagnosed sarcoidosis 
and pre-existing disease of variable durations.  
Volatile organic compounds  
The role of VOCs in discriminating participants with sarcoidosis from healthy controls was evaluated 
across four studies, (29) (30) (31) (32) (Table 7). One study (29) employed ion mobility spectrometry 
to identify characteristic peak VOC profiles in patients with confirmed sarcoidosis (n=5) compared to 
those with suspected sarcoidosis (n=4) who received an alternative diagnosis. Using principle 
component analysis, those with confirmed sarcoidosis had a highly congruent distribution of 
metabolites compared to those without sarcoidosis. 
Fijten and colleagues (31) performed gas chromatography and time-of-flight mass spectrometry in a 
two-part discovery and validation study. Nine discriminatory VOCs were found to predict sarcoidosis 
with 79.4% accuracy with a sensitivity and specificity of 75.4% and 92.5% respectively with sampling 
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undertaken during 2010-2012. The receiver operating characteristic (ROC) curve had an area under 
the curve (AUC) of 91.3%. During the validation phase, sampling took place at a different centre in the 
Netherlands during 2015 and the overall prediction rate was found to be 74.1% accurate with a 
sensitivity of 68.0% and specificity of 79.3%. The ROC curve had an AUC of 76.4%.  
A further study (32) evaluated a colorimeter array capable of identifying 36 VOCs in the detection of 
non-small cell lung cancer. In the clinical control group which included 20 subjects with sarcoidosis, a 
random forest model was generated from 70% of subjects which was validated with the remaining 
30%. When comparing sarcoid patients against all other study subjects, the model error rate was 10% 
with a validation sensitivity and specificity of 16.7% and 81.1% respectively (p=0.69). Using electric 
nose technology, Dragonieri et al (30) were able to differentiate untreated pulmonary sarcoidosis 
from healthy controls with a cross-validated accuracy of 83.3% (p<0.001).  
Considerable variation existed amongst the studies with respect to disease duration and smoking 
status which may affect the VOC profiles obtained; two recruited exclusively non-smokers or ex-
smokers in subjects with sarcoidosis (30) (32), however one study also included three smokers in the 
control group (32).  Fijten and colleagues (31) recruited current smokers in the discovery cohort, 
whereas the validation cohort consisted entirely of non-smokers, however subgroup analysis was 
performed to ensure this had no confounding effect. Furthermore, this was the only study which 
attempted to control for the confounding effect of exposure to exogenous  VOCs in the environment 
by performing sampling of controls in the same location as patients and recruiting spouses as healthy 
controls where possible. In addition, recruitment of spouses and partners as healthy controls also 
helped to minimise the influence of dietary exposure on the breath profiles.  
Miscellaneous breath-based biomarkers 
Total protein was explored in two studies (7) (23) both of which identified elevated concentrations in 
EBC, however only one demonstrated statistical significance when comparing to healthy controls 
(Table 5). Angiotensin converting enzyme (ACE) was detectable in 2/16 participants with sarcoidosis 
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and 3/20 healthy controls, and whilst mean values were not presented, the authors concluded no 
statistically significant difference between the two groups (23). Hepatocyte growth factor (HGF) was 
evaluated by Piotrowski et al (2010c) (33) and was detectable in 56% (36/64) of participants with 
sarcoidosis and 87% (13/15) of healthy controls, however no significant difference was observed 
between the two groups.  
Utility of breath-based biomarkers in differentiating between clinical phenotypes, disease activity, 
radiological stage or in correlation with traditional serological biomarkers used in clinical practice  
Ten studies classified patients into those with and without active disease, however, the criteria used 
for defining disease activity varied considerably amongst the studies (Table 3). Whilst most studies 
reported radiological stage, several did not assess or correlate the breath biomarker of interest in 
relation to the radiological stage. Correlation of the breath biomarker with pulmonary function tests 
or current serological biomarkers such as calcium, peripheral lymphocytes and ACE was also variable 
across the studies.  
Markers of oxidative stress  
No significant difference was reported in the mean concentration of carbon monoxide between those 
with active and inactive sarcoidosis. Furthermore, no correlation was observed with pulmonary 
function tests, serum ACE, radiological stage or clinical activity.  
Two studies evaluated the utility of 8-isoprostane in assessing disease activity according to the 
percentage of lymphocytes in BALF with conflicting results. Psathakis et al (20) reported significantly 
elevated 8-isoprostane levels in those with active disease on the basis of clinical symptoms and 
markers of disease activity including lymphocytic alveolitis (>18% lymphocytes in BALF) compared to 
healthy controls and those with inactive disease. No significant difference was observed between 
those with inactive disease and healthy controls and there was no correlation with radiological stage.  
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In contrast, Piotrowski et al (2007) (16) observed no such findings with respect to the percentage of 
lymphocytes in BALF, however, there was a trend of increasing 8-isoprostane with increasing 
radiological stage although this did not reach statistical significance. Elevated 8-isoprostane correlated 
with the percentage and number of eosinophils in BALF.  In two further studies, 8-isoprostane was 
higher in those with stage III disease compared to stage I disease (12) and when comparing stage III 
disease against healthy controls (17). No other significant difference was observed between 
radiological stages. Levels of 8-isoprostane in Piotrowski et al (2010b) (12) were detectable in 26/40 
(65%) of participants with sarcoidosis and 8/34 (24%) of healthy controls and subjects with 
undetectable 8-isoprostane were assigned a value half of the detection limit. Undetectable 8-
isoprostane occurred more frequently in controls and those with stage I disease compared to stages 
II and III disease and the authors concluded that during follow-up at 6-12 months, the chance of 
remission (relative risk) was 3.33 (95% confidence interval; 1.20-5.78) when 8-isoprostane was 
undetectable at baseline which was statistically significant.  
When evaluating somatostatin-receptor scintigraphy in assessing disease activity compared to 
traditional markers of disease activity, 8-isoprostane was significantly higher in those with a positive 
scan, compared to a negative scan indicative of inactive disease (15). 
Correlations between 8-isoprostane and various pre-existing biomarkers was not observed amongst 
the studies, with the exception of Psathakis et al (20) where 8-isoprostane correlated positively with 
serum ACE and Piotrowski et al (2010a) (17) where 8-isoprostane correlated negatively with the 
percentage of lymphocytes in BALF (See Table 4). 
Metallic elements  
In the two studies which explored metallic elements, Corradi et al (22) reported a positive correlation 
between iron in EBC and diffusion capacity of the lung for carbon monoxide (DLCO). The authors also 
reported no correlation with respect to disease severity, however the criteria used to classify disease 
severity was not specified. Mohan et al (7) reported no significant correlations between calcium and 
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radiological stage. Negative correlations were reported between EBC calcium and forced expiratory 
volume in one second (FEV1) and forced vital capacity (FVC) (See Table 5). 
Cytokines and markers of inflammation 
All studies with the exception of Loke et al (24) discussed the breath biomarker of interest in relation 
to radiological stage and reported no significant correlations were observed. In Piotrowski et al (2007) 
(16) there was a general trend of increasing LTB4 with increasing radiological stage, however this failed 
to reach statistical significance. Both neopterin and TGF-β1 demonstrated a general trend of increasing 
biomarker concentration with declining FEV1 (23). Alongside radiological stage, Piotrowski and 
colleagues (16) also classified participants with sarcoidosis according to percentage of lymphocytes in 
BALF, however no significant difference was observed in the mean concentration of CysLT or LTB4 in 
those with and without lymphocytic alveolitis (>18% lymphocytes) (See Table 5). 
Nitric oxide  
Across the six studies, four (13) (14) (18) (26) classified participants into those with and without active 
disease. Criteria and methods used to define and classify disease activity differed amongst the studies. 
In two studies, all participants had newly diagnosed sarcoidosis and were presumed to have active 
disease on the basis of clinical symptoms, extra pulmonary manifestations and elevated serum ACE in 
one study (13) and based upon clinical symptoms and elevated lymphocytes in BALF in the other (26).  
Two studies (14) (18) reported no significant difference between individuals with and without active 
disease. Five studies reported no significant differences in exhaled nitric oxide in relation to 
radiological stage (14) (18) (19) (25) (26). With the exception of a weak correlation between exhaled 
nitric oxide and DLCO (r=0.52, p=0.029) in Ziora et al, (18) and a negative correlation between CAlvNO, 
DLCO (r=-0.40, p=0.012) and FVC (r=-0.52, p=0.001) in Choi et al, (14) there were no other associations 
observed in any study between nitric oxide and any marker of disease activity or pre-existing 
biomarker (See Table 6). 
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Volatile organic compounds  
No studies assessed or reported differences in VOC profiles in relation to radiological stage, disease 
activity or correlation with pre-existing biomarkers (See Table 7). 
Miscellaneous breath-based biomarkers 
Of the two studies that evaluated concentration of total protein in EBC, one (7) reported no significant 
difference between participants of differing radiological stage, whereas in the remaining study (23) 
the relationship between total protein and radiological stage was not assessed. In Piotrowski et al 
(2010c) (33) all participants were considered to have active disease however there was no correlation 
observed with HGF or any parameter measured (See Table 5). 
The effect of treatment on the breath-based biomarker  
Six studies recruited participants that were treatment naïve (16) (17) (18) (25) (26) (33). In one study 
treatment status was not specified (32). Fourteen studies recruited participants receiving a range of 
treatments including inhaled and oral corticosteroids through to immunosuppressive agents. Only 
nine studies reported outcomes or differences in the breath biomarker with respect to the effect of 
treatment (7) (12) (13) (14) (19) (21) (22) (23) (30).  
Markers of oxidative stress  
No significant correlation was found between exhaled carbon monoxide and subjects receiving steroid 
therapy (21). Only one of the studies reporting 8-isoprostane assessed treatment effect; two recruited 
treatment naïve participants (16) (17) and the remaining two studies did not report the effect of 
treatment (20) (15). In the longitudinal study by Piotrowski et al (2010b) (12) all participants were 
treatment naïve at baseline and during follow-up over 6-12 months eight participants received 
treatment. Those treated with corticosteroids had significantly lower concentrations of 8-isoprostane 
(p=0.02), however the authors reported that a similar effect was not observed in those who 
underwent spontaneous remission (Table 4).  
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Metallic elements 
Corradi et al (22) reported no significant difference in the concentration of metallic elements in EBC 
was observed between treated and untreated participants (See Table 5). 
Cytokines and markers of inflammation  
Of the studies which assessed inflammatory cytokines, three recruited participants receiving 
treatment (7) (23) (24). In the remaining study (16) all participants were treatment naïve at enrolment.  
No significant difference was reported in neopterin or TGF-β1 between subjects receiving treatment 
compared to those not receiving treatment (23). Mohan and colleagues (7) reported that a patient 
with severe disease receiving treatment with intravenous, oral and inhaled corticosteroids had TNFα 
which was undetectable. The effect of treatment on IL-27 was not assessed or reported (24) (See Table 
5). 
Nitric oxide  
Three studies (13) (14) (19) included participants treated with inhaled or oral corticosteroids or a 
combination of steroids and immunosuppression. Moodley et al (13) reported that nitric oxide 
decreased from 9.8 ± 0.4 to 5.9 ± 1.4ppb, p=<0.01 at six weeks follow-up in eight patients treated with 
40mg prednisolone once daily. In contrast, Choi et al (14) observed no consistent pattern of change in 
nitric oxide at any flow rate, CAlvNO or flux of nitric oxide from the airway wall in six patients who 
received treatment and completed follow-up over 3-23 weeks duration. Cameli et al (19) reported no 
significant differences between treated and untreated participants and furthermore, Ziora et al (18) 
reported no significant differences between those with and without an indication for commencing 
treatment (See Table 6).  
Volatile organic compounds  
Three studies (29) (30) (31) included participants treated with steroids or immunosuppression, 
however only one study reported the effect of treatment on the VOC profile. Dragonieri and 
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colleagues (30) reported that participants with untreated sarcoidosis could be discriminated from 
healthy controls with a cross-validated accuracy of 83.3%, however breath-prints from patients with 
treated and untreated sarcoidosis could be discriminated less easily (See Table 7). 
Quality Assessment and Risk of Bias  
Included studies were all of relatively small sample size and of variable quality. Outcomes of the 
QUADAS-2 quality assessment are shown in Figures 3 and 4. Unclear risk of bias existed for the vast 
majority of studies with respect to participant selection due to the lack of clarity surrounding 
recruitment methods. It is unclear as to whether consecutive or random sampling occurred in order 
to enrol participants, or if highly selected patients with sarcoidosis were recruited. The vast majority 
of studies were cross-sectional and case-controlled in design and frequently there was inadequate 
matching for age and gender amongst control groups. There was considerable variation in sampling 
and analytical techniques all of which influence the results obtained in breath analysis making 
comparability difficult (28) (34) (35). Sample sizes were small and ranged from 5-87 participants with 
no power calculation reported in any study. With the exception of one study (31), all were single-
centre which ultimately limits the generalisability. Finally, in all studies it was unclear whether breath 
sampling and analysis was conducted by an investigator blinded to the participants’ disease status.  
Discussion  
This systematic review demonstrates that the evidence for the role of breath-based biomarkers in 
sarcoidosis remains inconclusive. Twenty-one studies were identified through electronic searches 
which assessed 25 individual breath-based biomarkers and expired VOCs. Many studies were of small 
sample size and varying quality with considerable heterogeneity in patient characteristics and 
populations recruited. In addition, the lack of gold standard for defining disease activity also 
contributed to the variability of the findings reported, particularly in studies which assessed the same 
biomarker such as exhaled nitric oxide and 8-isoprostane. With the exception of three studies, all were 
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cross-sectional in design and therefore the lack of longitudinal data makes it difficult to draw firm 
conclusions with regards to the clinical relevance and utility of potential biomarkers. 
Another concern was the variation in length of disease duration which ranged from those newly 
diagnosed to 11 years, particularly in studies which did not attempt to assess for active disease. Only 
seven studies (13) (14) (16) (17) (20) (25) (26) recruited participants with newly diagnosed disease 
which was likely to be active. Whilst sarcoidosis is often a self-limiting disease, resolving spontaneously 
within two years (3) the prolonged time lag between diagnosis and breath-sampling in several studies 
may have confounded results leading to false negatives. 
Amongst the studies which evaluated EBC and exhaled nitric oxide there was lack of standardisation 
in breath sampling and analytical techniques. Alongside many patient related factors, dilution of EBC 
and biomarkers at the lower limit of detection have been postulated as a cause of variability amongst 
studies (36). These disparities have been recently addressed by the European Research Society task 
force with recommendations put forward to standardise sampling and analytical techniques (34) (35).  
Of the ten EBC studies included in this review, six assigned an arbitrary value of half the lower limit of 
detection for biomarkers that were undetectable and specified the number of participants in which 
this applied to. In the remaining studies, Psathakis et al (20) did not specify a detection threshold, nor 
the proportion of subjects in which 8-isoprostane was undetectable or how this was handled during 
analysis, whereas, in Mohan et al, (7) TNFα was detectable in all but one subject from each cohort 
(sarcoid and controls). In contrast, Piotrowski et al (2012) (15) and Piotrowski et al (2010a) (17) 
specified a detection threshold of 5pg/ml and assigned an arbitrary value of half this lower limit in 
those with undetectable 8-isoprostane, however it is unclear as to the number of participants to which 
this applied. If these samples were comprised of mainly healthy controls or subjects with less severe 
clinical phenotypes of sarcoidosis, then assigning them a higher value could potentially nullify any 
possible differences observed between the groups of interest, in particular when comparing disease 
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severity and radiological stages. Whilst the concentration may be below the limit of detection it is also 
important to consider that lack of detection may reflect the true absence of the biomarker.  
Breath biomarkers investigated in sarcoidosis included markers of oxidative and nitrosative stress, 
cytokines, macrophage activation, metallic elements and VOCs. Oxidative stress has been implicated 
in a variety of interstitial lung diseases including sarcoidosis (37).  Markers of oxidative stress elevated 
in sarcoidosis included carbon monoxide and 8-isoprostane. Other markers such as hydrogen peroxide 
and ethane have also been reported to be higher in sarcoidosis and other forms of interstitial lung 
disease (38) (39). Given its low specificity alongside the influence of passive and active smoking, 
exhaled carbon monoxide is unlikely to be of clinical utility (21). 8-isoprostane is a prostaglandin-like 
compound produced by free-radical oxidation of arachidonic acid (40). Elevated 8-isoprostane has 
been identified in both serum and BAL in sarcoid patients, however was not found to correlate with 
markers of disease activity including FVC, DLCO or oxygen saturation (41). Evidence from EBC supports 
this (12) (16) (17) (20), reflecting a role for oxidative stress in the pathophysiology of sarcoidosis. 
However, its use as a discriminative diagnostic biomarker is uncertain as 8-isoprostane has been 
shown to be elevated in other forms of interstitial lung disease including idiopathic pulmonary fibrosis 
(42), systemic sclerosis (43) and non-fibrotic lung diseases such as asthma (44).  Conflicting results 
were observed with respect to disease activity, and whilst there was a trend for increasing 8-
isoprostane with advancing radiological stage, this was not statistically significant in one study. 
Piotrowski et al (2010b) (12) reported that undetectable 8-isoprostane at baseline may predispose to 
increased chances of early remission, however, it was also observed that such patients could present 
during follow-up with elevated 8-isoprostane in the absence of clinical signs and symptoms of disease. 
The authors concluded that given the short period of follow-up it was unclear if such patients were at 
risk of future relapse or flare. Further research with larger powered studies and longer follow-up 
periods are therefore required to assess its potential role as a prognostic marker.  
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Several cytokines including TNFα and TGF-β1 have been shown to be implicated in the pathogenesis 
of sarcoidosis and augmentation of inflammation (6). Additionally, TNFα is elevated in those with 
active disease (45). Whilst TNFα and TGF-β1 in EBC were significantly elevated in sarcoidosis compared 
to controls in keeping with previous research, neither correlated with clinical activity or radiological 
stage, however, there was a trend for increasing TGF-β1 and declining FEV1 which was not statistically 
significant and again most likely reflected insufficient power to detect significant differences. 
Neopterin is a metabolite of guanosine triphosphate secreted from activated macrophages (6). Serum 
and urinary levels appear to correlate with disease activity, radiological stage and likelihood of 
spontaneous remission (6) (46) (47). Although neopterin was significantly higher amongst those with 
sarcoid, it was only detected in 7 of 16 patients and again failed to correlate with disease activity, 
radiological stage or response to treatment. This indicates the need for not only a larger cohort study, 
but also a more sensitive detection method for biomarkers which may only be present in extremely 
dilute concentrations.  
Nitric oxide is a marker of nitrosative stress which has largely been evaluated as a biomarker in asthma 
(28). It has also been shown to be elevated in a variety of interstitial lung diseases (48). Multiple factors 
have been shown to influence the fraction of exhaled  nitric oxide including spirometric manoeuvres, 
exercise, concurrent steroid medication , inhaled corticosteroids and atopy (28). In addition, smoking 
lowers exhaled nitric oxide (49). Given the heterogeneity across the six studies assessing nitric oxide 
coupled with inadequate control for many of these confounding factors it is likely this gave rise to the 
conflicting results observed. Whilst four studies recruited non-atopic healthy controls, Choi et al (14) 
also recruited participants with concurrent asthma. The effect of atopy was only evaluated in one 
study, Wilsher et al (25), which demonstrated significantly elevated levels of nitric oxide in atopic 
sarcoid patients compared to non-atopic sarcoid patients.  It is unclear as to whether or not atopy 
confounded the positive findings observed in both Ziora et al and Moodley et al (13) (18). Both Wilsher 
et al and Choi et al also included current smokers in comparison to control groups consisting of non-
smokers which may have confounded results. Differences in baseline participant characteristics and 
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treatment exposures may have also accounted for the differing results obtained. Moodley and 
colleagues recruited only African and Asian participants, nearly all of whom had extra-pulmonary 
manifestations with raised serum ACE. This cohort are more likely to have represented those with 
more severe disease possibly accounting for higher mean baseline concentrations of exhaled nitric 
oxide in comparison to those studies which exclusively recruited Caucasians. Cameli et al reported no 
differences between untreated and those treated with oral steroids, however, in Choi et al, 69% of 
participants with sarcoidosis were prescribed inhaled corticosteroids and it is unclear if this supressed 
the level of exhaled nitric oxide as no subgroup analysis took place with the 31% not receiving inhaled 
corticosteroid. Similarly to 8-isoprostane, the lack of specificity of exhaled nitric oxide coupled with 
multiple factors influencing levels of nitric oxide limit its use as a diagnostic tool. Furthermore, there 
is no robust evidence to support its use for prognostication or monitoring in sarcoidosis.  
There has been a growing interest into VOCs as a potential source of biomarkers in respiratory disease 
(50) (51). Highly sensitive analytical techniques such as gas chromatography-mass spectrometry have 
facilitated discovery and identification of novel VOCs in a range of respiratory diseases including 
pneumonia, asthma, chronic obstructive pulmonary disease, lung cancer and idiopathic pulmonary 
fibrosis (52) (53) (54). Of all the breath-based biomarkers evaluated in this review, VOCs have shown 
promising potential, particularly as a diagnostic tool to distinguish sarcoidosis from health. 
Fijten et al (31) identified a set of nine compounds which discriminated between sarcoidosis and 
healthy controls. These included isoprene, 2-methylpentane, benzene, 3-methylhexane, p-
Benzoquinone, phenol, D-Limonene and dibenzofuran all of which were present in lower 
concentrations in sarcoidosis. In contrast, the concentration of iodomethylcyclopentane was elevated 
in exhaled breath from sarcoidosis patients compared to controls.  
Isoprene is a by-product of normal cholesterol synthesis and prominent in exhaled breath (55). 
Reduced exhaled isoprene has been observed in lung cancer and may therefore be of limited use as a 
biomarker in sarcoidosis (56) (57). The branched alkanes 3-methylhexane and 2-methylpentane are 
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thought to represent pollutants and their biosynthesis is thought to relate to changes in oxidative 
stress (31). Interestingly, despite representing the greatest importance in the classification model with 
the highest statistical significance, their concentration was found to be lower in sarcoidosis compared 
to controls. This is conflicting in relation to other markers of oxidative stress such as 8-isoprostane and 
hydrogen peroxide which are elevated in sarcoidosis and interstitial lung diseases. Phenol is 
metabolised endogenously from benzene and previous research has demonstrated background 
emission from Tedlar bags (58). Fijten and colleagues therefore remarked that the role of phenol as a 
discriminatory VOC in sarcoidosis requires interpretation with caution. Dibenzofuran and 
iodomethylcyclopentane have not previously been identified in exhaled breath and therefore the 
presence in patients with sarcoidosis warrants further exploration (31). Dragonieri et al (30) reported 
the breath prints between healthy controls and treated sarcoidosis patients were indistinguishable 
suggesting normalisation of the breath profile following treatment. VOCs could therefore be used to 
monitor treatment response. Further longitudinal data is required to explore how the VOC profile 
changes over time and correlates with disease activity, pulmonary function tests and serological 
markers. In addition, rigorous validation should be undertaken as only one study evaluating VOCs, 
Fijten et al, sought to externally validate their dataset by sampling at both a different time and 
location.  
Limitations  
There are several limitations to this systematic review. Firstly, only studies published in English 
language were included. The search strategy identified three further studies, two of which were 
published in Polish (39) (59) and one in German (60). Secondly, a rigorous inclusion criteria was applied 
with respect to the methods surrounding diagnosis of sarcoidosis. As such, this resulted in the 
exclusion of two papers due to insufficient details surrounding the diagnostic criteria for sarcoidosis 
(61, 62). We attempted to contact the authors for further clarification, however did not receive any 
correspondence. One of these papers by Antczak et al (62) aimed to correlate eicosanoids in BALF and 
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EBC in a variety of respiratory diseases including sarcoidosis. Furthermore, and similar to Psathakis et 
al, those with active disease and a lymphocytic alveolitis >18% had significantly higher concentrations 
of 8-isoprostane in EBC and BAL fluid compared to those with non-active disease. This strict inclusion 
criteria was justified as with all reviews surrounding a diagnostic test of accuracy in order to improve 
validity. Finally, due to variation in reporting methods and a lack of homogeneity, it was not possible 
to combine, for meta-analysis, all studies which evaluated the same biomarker.   
Conclusions and directions for future research  
Whilst various breath-based biomarkers have been assessed in sarcoidosis, the strength of the 
evidence remains weak and inconclusive. This reflects the poor quality and variability in terms of 
design, methodology and small sample sizes across the spectrum of studies. Under-powering 
alongside difficulties in identifying biomarkers likely to be highly diluted in breath samples may have 
both contributed in failures to detect statistically significant differences. It seems unlikely that a single 
component in exhaled breath would be of diagnostic value due to lack of sensitivity and specificity. 
Further research is required to assess the utility of these biomarkers in the prognostic setting. Early 
research involving VOCs has shown promising potential and may provide a unique breath-print which 
could not only aid diagnosis, but also aid clinical phenotyping to identify those at risk of chronic disease 
or relapse, and also monitor response to treatment. Ideally, studies should involve much larger sample 
sizes across multiple centres and be longitudinal in design thus allowing sequential monitoring of 
breath-biomarkers over time. Standardised and validated methods should also be established in both 
the sampling and analysis of breath components.  
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Figure 1: PRISMA 2009 Flow diagram.  
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Figure 2: Continuous random-effects meta-analysis of the mean difference of alveolar nitric oxide in 
sarcoidosis compared to healthy controls. Study weights: O’Donnell et al 20.18%, Moodley et al 
27.52%, Choi et al 25.64% and Cameli et al 26.66%.  
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Author / 
Year 
Country  Study 
Design  
Biomarker Sarcoidosis 
(n),  
age (years),  
% male 
Healthy 
Controls (n), 
age (years), 
% male 
Ethnicity  Smoking Status  
(current/ex/never) 
(Sarcoidosis)  
(Healthy Controls) 
Diagnostic 
Methods  
Disease 
Duration  
Radiological 
Stage 
(0/I/II/III/IV) 
Treatment 
Exposure  
O’Donnell 
et al 
(1997) 
(26) 
Ireland  Cross-
sectional 
case-control 
Nitric oxide  
(Peak, end-
tidal and 
CALVNO) 
n=10               
35.5 (22-
63)*    
80% 
n=12                
28.2 (22-44)*     
66% 
Irish 
Caucasian 
(n=10) 
Not specified  
All non-smokers 
 
Biopsy 
(n=10) 
Newly 
diagnosed 
(n=10) 
0/4/3/2/1 All treatment naïve  
Moodley 
et al 
(1999) 
(13) 
South Africa Longitudinal  Nitric oxide  
(Alveolar) 
n=12  
41 ± 2.1† 
50%  
n=21   
42 ± 3.8†  
48% 
 
African 
(n=10) 
Asian (n=2) 
Not specified  
All non-smokers 
Biopsy 
(n=12) 
Newly 
diagnosed 
(n=12) 
0/2/9/1/0 All treatment naïve 
at baseline. At six 
weeks follow-up 
n=8 received 
steroid treatment  
Ziora et al 
(2004) 
(18) 
Poland  Cross-
sectional 
case-control 
Nitric oxide  
(Mean end 
expiratory)  
n=27  
26-67*  
67%  
N=11 
31-52* 
73% 
 
Caucasian 
(n=27) 
All non-smokers 
All non-smokers  
Biopsy 
(n=27) 
Disease 
duration <2 
years 
0/6/10/11/0 All treatment naïve. 
Treatment 
indicated in n=12 
Psathakis 
et al 
(2004) 
(20) 
Greece  Cross-
sectional 
case-control 
8-
isoprostane  
n=30 
48 ± 14 
33%  
n=12 
39 ± 9.0 
42%  
 
 
Not 
specified  
All non-smokers  
All non-smokers 
Biopsy 
(n=30) 
Newly 
diagnosed 
(n=7), 
Established 
(n=23) with 
a duration 
of 3±2 years  
4/6/11/8/1 Oral steroids (n=9) 
Wilsher et 
al (2005) 
(25) 
New 
Zealand  
Cross-
sectional 
case-control 
Nitric oxide  
(Plateau of 
end 
expiration 
when carbon 
dioxide 70-
80% of 
maximum) 
n=52 
42 (23-66)* 
56% 
n=44  
Age & 
gender not 
specified  
 
 
Caucasian 
(n=41), 
Indian 
(n=5), 
Polynesian 
(n=4), 
African 
(n=1), 
Asian (n=1) 
7/5/40 
All non-smokers 
Biopsy or 
clinico-
radiologically 
Newly 
diagnosed 
(n=15), 
Established 
disease 
(n=37). 
Duration not 
specified 
3/13/21/14/1 All treatment free  
at enrolment and 
during preceding 3 
months 
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Piotrowski 
et al 
(2007) 
(16) 
Poland  Cross-
sectional 
case-control 
8-
isoprostane 
CysLT 
LTB4  
n=28 
39.2 ± 2.0† 
64%  
n=17 
39.8 ± 2.6† 
53% 
 
 
Not 
specified  
All non-smokers  
All non-smokers 
Biopsy 
(n=23), 
clinic-
radiologically 
as per 
guidelines 
(n=5) (1) 
Newly 
diagnosed 
(n=28), 
disease 
duration <3 
months  
0/8/10/10/0 All treatment naïve  
Mazzone 
et al 
(2007) 
(32) 
USA  Cross-
sectional 
case-control 
VOCs  n=20 
53 (41-75)* 
25% 
n=21  
55 (36-70)* 
52% 
 
 
Not 
specified  
0/4/16 
3/9/9 
Biopsy and 
clinic-
radiologically 
Not 
specified  
Not specified  Not specified, 
however treatment 
status was not 
criteria for 
exclusion  
Westhoff 
et al 
(2007) 
(29) 
Germany  Cross-
sectional  
 VOCs n=5  
49 (30-67)* 
Incomplete 
data for 
gender  
Alternative 
diagnoses 
n=4  
63.5 (60-65)* 
Incomplete 
data for 
gender  
Not 
specified  
Not specified  
Not specified 
Biopsy (n=4) 
Clinico-
radiologically 
(n=1) 
Not 
specified  
Incomplete 
data 
Oral steroids (n=1), 
otherwise not 
stated 
 
Ciarleglio 
et al 
(2008) 
(21) 
Italy  Cross-
sectional 
case-control 
Carbon 
monoxide  
n=78 
52 ± 13 
32%  
n=25 
39 ± 20 
32%  
 
 
Not 
specified  
Non-smokers for 
>12 months  
Non-smokers for 
>12 months 
As per 
international 
guidelines 
(63) 
Not 
specified  
14/19/20/25/0 Oral steroids (n=33)  
Choi et al 
(2009) 
(14) 
 USA  Longitudinal  Nitric oxide  
 
(Various flow 
rates, 
CALVNO, 
JAWNO)  
n=42 
46.0 ± 12.2 
(active) 
51.7 ± 10.7 
(inactive) 
64%  
n=20 
45.4 ± 10.3 
50% 
 
 
Caucasian 
(n=25), 
African 
American 
(n=17) 
1/1/6 (active) 
3/11/20 (inactive) 
All never smokers 
Biopsy 
(n=42) 
New and 
established. 
Duration 
48.6 ± 73.7 
months 
(active), 
92.2 ± 107.3 
months 
(inactive). 
6/11/19/3/3 All treatment naïve 
at baseline to oral 
steroids, n=29 
treated with ICS. At 
3-23 week-follow-
up n=6 received 
treatment with 
steroids ± 
methotrexate 
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Corradi et 
al (2009) 
(22) 
Italy  Cross-
sectional 
case-control 
Metallic 
elements:  
Aluminium  
Lead 
Nickel 
Chromium  
Silicon  
Cobalt  
Calcium  
Zinc  
Iron  
Copper  
Selenium  
Manganese  
Molybdenum 
n=22 
53.5 ± 13.9 
64%  
n=33 
55 ± 10.8 
76%  
 
 
Not 
specified  
0/16/6 - 16.5 (5.3-
20.0) pack years 
 
All non-smokers 
Biopsy 
(n=22) as per 
guidelines 
(1) 
Not 
specified  
Not specified  Oral steroids (n=6), 
Combined steroids 
& 
immunosuppression 
(n=4) 
Piotrowski 
et al 
(2010a) 
(17) 
Poland  Cross-
sectional 
case-control 
8-
isoprostane  
n=29 
40.2 ± 2.0 
55% 
n=34 
39.8 ± 2.6 
41% 
 
 
Not 
specified  
All non-smokers  
 
All never smokers 
Biopsy 
(n=29) 
Newly 
diagnosed 
(n=29) 
0/9/14/6/0 All treatment naïve  
Piotrowski 
et al 
(2010b) 
(12) 
Poland  Longitudinal  8-
isoprostane  
n=40 
39 ± 11 
43%  
n=34 
45 ± 10 
44%  
 
 
Caucasian 
(n=40) 
All non-smokers  
 
All never smokers 
Biopsy or 
clinico-
radiologically 
as per 
guidelines 
(1) 
Median of 
10 (4-60) 
weeks 
duration 
from 
symptom 
onset to 
baseline 
visit 
0/23/9/8/0 All treatment naïve 
for >12 months at 
baseline. At follow-
up (n=8) received 
treatment with 
steroids.  
Piotrowski 
et al 
(2010c)  
(33) 
Poland  Cross-
sectional 
case-control 
HGF  n=64 
39±2.0 
(stage I)† 
42±2.0 
(stage II)† 
40±3.0 
(stage III)† 
n=15  
Age & 
gender not 
specified  
 
 
Not 
specified  
0/14/50 - <10 pack 
years 
 
All never smokers 
Biopsy or 
clinico-
radiologically 
Established 
disease 
duration 
ranging 
from 48 ± 25 
– 120 ± 41 
weeks  
Stages I – III (n 
for each stage 
not specified) 
All treatment naïve 
at time of sampling   
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Gender not 
specified  
 
Piotrowski 
et al 
(2012) 
(15) 
Poland  Cross-
sectional  
8-
isoprostane  
n=32 
43 ± 12 
53%  
(Sarcoidosis 
patients with 
negative 
somatostatin 
scintigraphy 
considered 
negative 
controls) 
n=12 
41.0 ± 10.0 
50% 
Not 
specified  
All non-smokers  Biopsy 
(n=32) as per 
guidelines 
(1) 
Not 
specified  
4/15/8/3/2 Oral steroids (n=9) 
Ahmadzai 
et al 
(2013) 
(23) 
Australia  Cross-
sectional 
case-control 
Neopterin 
TGF-β1 
ACE 
Total protein 
n=16 
48.5≠ 
69% 
n=22 
37≠ 
59% 
 
 
 
Not 
specified  
0/9/7 
 
1/5/16 
As per 
international 
guidelines 
(1) 
Established 
disease 
(n=16), 
disease 
duration 7.5 
± 6.7 years 
1/6/6/1/2 Oral steroids (n=3), 
steroids and 
methotrexate (n=1) 
Dragonieri 
et al 
(2013) 
(30) 
Netherlands  Cross-
sectional 
case-control 
VOCs n=31 
48.4 ± 9.0 
(untreated) 
49.7 ± 7.9 
(treated) 
55% 
n=25 
39.6 ± 14.1 
44% 
 
 
Not 
specified  
0/0/31 
 
All never smokers 
Biopsy or 
clinico-
radiologically 
Established 
disease, 
duration 6.8 
± 5.5 years 
(untreated) 
and 11.1 ± 
6.5 years 
(treated) 
1/2/5/2/1 
(untreated) 
2/2/2/1/13 
(treated) 
Oral steroids 
(n=12), steroids & 
azathioprine (n=4), 
methotrexate (n=1) 
or 
hydroxychloroquine 
(n=3) 
Loke et al 
(2015) 
(24) 
Australia  Cross-
sectional 
case-control 
IL-27 n=18 
50.3 ± 10.5 
61% 
n=21 
39.7 ± 19.7 
33% 
 
 
Not 
specified  
1/7/10 
 
0/6/15 
As per 
international 
guidelines 
(1) 
Established 
disease, 
duration 
6.72 ± 6.71 
years 
2/2/8/0/6 Combinations of 
steroids, 
azathioprine or 
mycophenolate 
(n=4) 
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Cameli et 
al (2016) 
(19) 
Italy  Cross-
sectional 
case-control 
Nitric oxide  
 
(Various flow 
rates, 
CALVNO) 
n=31 
55.7 ± 12.6 
Gender not 
specified 
n=30 
62.0 ± 4.7 
Gender not 
specified 
 
 
Not 
specified  
Ex-smokers (n=5) - 
1.8 ± 5.7 pack 
years 
 
7 ex-smokers 
As per 
international 
guidelines 
(1) 
Not 
specified  
0/0/17/14/0 Oral steroids (n=11) 
Mohan et 
al (2016) 
(7) 
Australia  Cross-
sectional 
case-control 
TNFα 
Calcium 
Total protein 
n=17  
50.06 ± 
2.62† 
65% 
 
n=23 
43.48 ± 2.93† 
61% 
 
Not 
specified  
0/8/9 
 
0/8/15 
Physician led 
and 
radiological 
staging as 
per 
international 
guidelines 
(1) 
Not 
specified  
7/0/6 (Stages II-
III)/4 
Combinations of 
oral/ inhaled 
steroids or 
immunosuppression 
(n=12) 
Fijten et al 
(2017) 
(31) 
Netherlands  Cross-
sectional 
case-control 
discovery/ 
validation 
study 
VOCs n=87 
(discovery) 
50.6 ± 10.6 
57% 
 
n=25 
(validation) 
53.4 ± 11.5 
64% 
n=26  
50.5 ± 10.9 
38% 
 
n=29 
51.2 ± 9.8 
41% 
 
 
Not 
specified  
7/12/68 
(discovery) 
0/0/25 (validation) 
 
3/10/13 
(discovery) 
Incomplete data 
(validation cohort) 
 
Biopsy or 
clinico-
radiologically 
as per 
guidelines 
(64) 
Established 
disease, 
with 
sampling 
during 2010-
2012 for 
discovery 
cohort and 
2015 for 
validation 
cohort.  
18/12/24/10/23 
(discovery) 
5/3/7/3/7 
(validation) 
n=40 (discovery)  
n=19 (validation) 
 
Table 1: Characteristics of included studies. Data expressed as mean and standard deviation unless otherwise stated. *Mean and Range; †Mean and SEM; ≠Median; ††Median 
(25-75th percentile); ¥Mean and 95% confidence intervals. CALVNO, Calculated alveolar concentration of exhaled nitric oxide; CysLT, Cysteinyl leukotrienes; LTB4, Leukotriene B4; 
VOCs, Volatile organic compounds; JAWNO, Flux of nitric oxide from the airway wall; HGF, Hepatocyte growth factor; TGF-β1, Transforming growth factor beta; ACE, Angiotensin 
converting enzyme; IL-27, Interleukin-27; TNFα, Tumour necrosis factor; ICS, Inhaled corticosteroids; vs, versus; USA, United States of America. 
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Author (Year) Biomarkers Biological Sample Collection Device  Method of Analysis  Detection Limit 
O’Donnell et 
al (1997)(26) 
Nitric oxide  
(Peak, end-tidal & CALVNO) 
Exhaled Breath  Logan Research LR2000 Chemiluminescence 
Analyser  
Chemiluminescence  1ppb 
Moodley et al 
(1999) (13) 
Nitric oxide  
(Alveolar)  
Exhaled Breath  Logan Research LR2000 Chemiluminescence 
Analyser 
Chemiluminescence  1-5000ppb 
Ziora et al 
(2004) (18) 
Nitric oxide  
(Mean end expiratory) 
Exhaled Breath  Seivers ‘280’ Chemiluminescence Analyser  Chemiluminescence <1ppb  
Psathakis et 
al (2004) (20) 
8-isoprostane EBC  Customised Device  Specific enzyme based immunoassay (Cayman 
Chemicals; Ann Arbor, Michigan) 
Not specified  
Wilsher et al 
(2005) (25) 
Nitric oxide  
(Plateau of end expiration 
when carbon dioxide 70-
80% of maximum) 
Exhaled Breath  Logan Research LR2000 Chemiluminescence 
Analyser 
Chemiluminescence  1-5000ppb  
Piotrowski et 
al (2007) (16) 
8-isoprostane  
CysLT  
LTB4 
EBC  EcoScreen Device  Specific enzyme based immunoassay (Cayman 
Chemicals; Ann Arbor, Michigan)  
8-isoprostane 5pg/mL 
CysLT 13pg/mL 
LTB4 4.43pg/mL 
Mazzone et al 
(2007) (32) 
VOCs  Exhaled Breath  Colorimetric Sensor Device  Colorimetric assay sensitive for 36 VOCs 
(colour changes converted into numerical 
vectors)  
Lower ppm to upper ppb 
Westhoff et 
al (2007) (29) 
VOCs  Exhaled Breath  Direct port connected to a 6-way valve and 
multi-capillary column on Ion mobility 
spectrometer 
Ion mobility spectrometer  Not specified  
Ciarleglio et 
al (2008) (21) 
Carbon monoxide  Exhaled Breath  Smokerlyzer Analyser Electrochemical sensor  1ppm  
Choi et al 
(2009) (14) 
Nitric oxide 
(Various flow rates, 
CALVNO, JAWNO) 
Exhaled Breath Logan Research LR1800 Chemiluminescence 
Analyser  
Chemiluminescence  1-5000ppb 
Corradi et al 
(2009) (22) 
Metallic elements EBC TURBO-DECCS Portable Condenser  Inductively coupled plasma mass 
spectrometry  
0.005µg/L 
Piotrowski et 
al (2010a)  
(17) 
8-isoprostane  EBC  EcoScreen Device  Specific enzyme based immunoassay Cayman 
Chemicals; Ann Arbor, Michigan) 
5pg/mL  
Piotrowski et 
al (2010b)  
(12) 
8-isoprostane  EBC  EcoScreen Device Specific enzyme based immunoassay Cayman 
Chemicals; Ann Arbor, Michigan) 
5pg/mL 
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Piotrowski et 
al (2010c)  
(33) 
Hepatocyte growth factor  EBC  EcoScreen Device Specific Immunoassay Kit (BioSource Europe 
S.A., Belgium)  
20pg/mL 
Piotrowski et 
al (2012)  (15) 
8-isoprostane  EBC  EcoScreen Device  Specific enzyme based immunoassay Cayman 
Chemicals; Ann Arbor, Michigan) 
 
5pg/mL  
Ahmadzai et 
al (2013) (23) 
Neopterin 
TGF-β1 
ACE 
Total protein 
EBC  Customised Device  Neopterin: ELISA (GenWay Biotech. San Diego, 
USA),  
TGF-β1: ELISA (GE Healthcare, 
Buckinghamshire, UK),  
ACE: Colorimetric assay (Buhlmann 
Laboratories, Switzerland), 
Total protein: QuantiPro bicinchoninic assay 
(Sigma-Aldrich, Sydney, Australia)  
Neopterin 0.7nmol/L 
TGF-β1 15pg/mL 
ACE 2.6 U/L 
Total protein 4mg/mL 
Dragonieri et 
al (2013) (30) 
VOCs  Exhaled Breath  Tedlar Bag  Electric Nose sensitive to 32 organic polymers 
(Cyranose 320, Smith Detectors, USA) 
Not specified  
Loke et al 
(2015) (24) 
IL-27 EBC and blood EcoScreen Device  ELISA (R&D Systems, USA) 156.3pg/mL 
Cameli et al 
(2016) (19) 
Nitric oxide  
(Various flow rates, 
CALVNO) 
Exhaled Breath  Modified Hypair FeNO Device  Chemiluminescence  Not specified  
Mohan et al 
(2016) (7) 
TNFα 
Calcium  
Total protein 
EBC  EcoScreen Device  TNFα: ELISA (Invitrogen, Camarillo, USA),  
Calcium: Inductively coupled plasma mass 
spectroscopy (PerkinElmer, Melbourne, 
Australia), 
Total Protein: QuantiPro bicinchoninic assay 
(Sigma-Aldrich, Sydney, Australia) 
TNFα 0-32pg/mL 
Calcium 5.0µg/L 
Protein 1-20µg/mL 
Fijten et al 
(2017) (31) 
VOCs Exhaled Breath  Tedlar Bag (5L for discovery study and 3L for 
validation study) 
Thermal Desorption followed by Gas 
Chromatography and Time-of-Flight mass 
spectrometry (Differing instruments were 
utilised between the discovery and validation 
studies) 
Not specified  
 
Table 2: Biomarker sampling and analytical methods. Same key as per table 1; EBC, Exhaled breath condensate; ELISA, Enzyme-linked immunosorbent assay; ppb, parts-per-
billion; ppm, parts-per-million; pg, picograms; µg, micrograms.    
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Author (Year) Biomarker (n) 
Total 
(n) 
Active 
Disease 
Specific Criteria used to Define Participants with Active Disease 
O’Donnell et 
al (1997)(26) 
Nitric oxide  
(Peak, end-tidal and CALVNO) 
10 10 Clinical symptoms, abnormal radiology, serological markers (ACE), BAL (elevated lymphocytic count, CD4:CD8 ratio). 
Moodley et al 
(1999) (13) 
Nitric oxide  
(Alveolar) 
12 12 Clinical symptoms, extra-pulmonary manifestations, abnormal radiology, serological markers (ACE), BAL (CD4:CD8 
ratio) and FEV1. 
Ziora et al 
(2004) (18) 
Nitric oxide  
(Mean end expiratory) 
27 21 Clinical symptoms, radiological features, serological markers and BAL based upon the American Thoracic Society, 
European Respiratory Society and World Association of Sarcoidosis and other Granulomatous Disorders criteria (1).  
Psathakis et 
al (2004) (20) 
8-isoprostane  30 14 Clinical symptoms alongside any one of the following: radiological progression over preceding three months on chest 
radiograph or presence of ground glass opacification on high resolution computerised tomography, serological markers 
(ACE, calcium, liver enzymes), BAL (lymphocytic alveolitis >18%, CD4:CD8 ratio >3.5) or decline in pulmonary function 
tests over preceding three months (>10% or >200ml decline in lung volumes or >15% or >3ml/min/mmHg for DLCO). 
Piotrowski et 
al (2007) (16) 
8-isoprostane 
CysLT  
LTB4 
28  BALF lymphocytic counts (lymphocytic alveolitis >18% n=19, lymphocytic counts <17% n=9). 
Ciarleglio et 
al (2008) (21) 
Carbon monoxide  78 47 Clinical symptoms alongside any of the following: extra-pulmonary manifestations, evidence of radiological 
progression, serological markers (ACE, calcium), BAL (CD4:CD8 ratio >2.5) or decline in pulmonary function tests.   
Choi et al 
(2009) (14) 
Nitric oxide 
(Various flow rates, CALVNO, 
JAWNO) 
42 8 Active disease was evident when >3 of the following criteria were met over a 6-12 week period: progression of 
respiratory symptoms, exercise desaturation >10% using pulse oximetry, decline in FVC or DLCO >10% or radiological 
progression.  
Piotrowski et 
al (2010b)  
(12) 
8-isoprostane  40  Disease activity assessed during follow-up using a scoring system according to the following: clinical symptoms, 
presence of Lofgren syndrome, extra-pulmonary manifestations, radiological progression on chest radiograph, 
serological markers (ACE, calcium, CRP), urinary calcium and decline in pulmonary function tests.  
Piotrowski et 
al (2010c)  
(33) 
Hepatocyte growth factor  64 64 Clinical symptoms, evidence of radiological progression, serological markers (ACE, calcium), BAL (elevated lymphocytic 
counts). 
Piotrowski et 
al (2012)  (15) 
8-isoprostane  32 20 Somatostatin receptor scintigraphy scan. A negative scan (n=12) was consistent with inactive disease.  
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Table 3: Criteria used to define and assess disease activity in studies which classified participants into those with and without active disease. Same key as per table 1; BAL, 
Bronchoalveolar lavage; FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity; DLCO, Diffusion capacity for carbon monoxide; CRP; C-reactive protein.  
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Author 
(year) 
Biomarker Differentiating Sarcoidosis from Healthy 
Controls 
(Sarcoidosis versus healthy controls) 
Differentiating Between Radiological 
Stage or Disease Activity 
  
Correlation with Pre-existing Clinical 
Biomarkers 
Effects with Respect to Treatment  
Psathakis 
et al 
(2004) (20) 
8-
isoprostane  
All sarcoidosis patients vs healthy controls:  
64.23 (37.00-91.46) vs 20.75 (16.06-25.44) 
pg/mL; p = 0.04.¥  
 
Inactive sarcoidosis vs healthy controls 
22.94 (15.89-29.99) vs 20.75 (16.06-25.44) 
pg/mL; p = >0.05¥ 
 
Active vs inactive sarcoidosis:  111.40 
(62.56-160.30) vs 22.94 (15.89-29.99) 
pg/mL;  p = <0.001¥ 
 
No significant differences reported 
according to radiological stage (p = 
0.2) 
8-isoprostane correlated positively 
with serum ACE (r =0.69, p = <0.0001) 
 
No correlations reported in relation to 
pulmonary function tests and serum 
calcium (p = >0.05) 
 
Not assessed or reported  
 
 
Piotrowski 
et al 
(2007) (16) 
8-
isoprostane 
CysLT 
LTB4  
8-isoprostane: 13.95 ± 2.59  vs 2.67 ± 
0.16pg/mL;  p = 0.0003† 
 
 
 
No difference reported according to 
clinical activity or radiological stage (p 
= >0.05)  
 
8-isoprostane increased with 
radiological stage, however did not 
reach statistical significance (p = >0.05) 
No correlations reported in relation to 
DLCO (p = >0.05) 
Treatment naïve  
Ciarleglio 
et al 
(2008) (21) 
Carbon 
monoxide  
3.3 (2.9-3.8) vs 1.4 (1.2-1.7)ppm; p<0.001¥ Active sarcoidosis vs healthy controls: 
3.3 (2.9-3.8) vs 1.4; (1.3-1.7)ppm; p = 
<0.001¥ 
 
Inactive sarcoidosis vs healthy 
controls: 2.7 (2.1-3.3) vs 1.4 (1.3-
1.7)ppm; p = <0.001¥ 
 
No significant differences reported 
according to clinical activity or 
radiological stage (p-values not 
reported) 
No significant correlations reported in 
relation to pulmonary function tests or 
ACE (p-values not reported).  
No significant differences reported 
in relation to steroid treatment (p-
values not reported) 
Piotrowski 
et al  
(2010a) 
(17) 
8-
isoprostane  
6.20; 2.50-16.95 vs 2.50; 2.50-3.90pg/mL; 
p = <0.05†† 
No significant differences reported 
according to radiological stage, 
however significance was highest 
when comparing stage III disease with 
healthy controls: 26.35; 3.90-33.85 vs 
2.50; 2.50-3.90pg/ml; p = <0.01 ††  
8-isoprostane correlated negatively 
with percentage of lymphocytes in BAL 
fluid (r = -0.40, p = 0.03) 
Treatment naïve  
Piotrowski 
et al  
8-
isoprostane  
8.50; 2.50-17.40 vs 2.50; 2.50-3.90pg/mL, 
p = 0.001†† 
8-isoprostane concentration was 
significantly higher in stage III 
compared to stage I disease (p = 0.03) 
No significant correlations reported in 
relation to pulmonary function tests or 
At follow-up 8-isoprostane 
significantly decreased in those 
treated with steroids (p = 0.02).  
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(2010b) 
(12) 
laboratory parameters (ACE, BAL cell 
counts, CRP, Ca2+) (p = >0.05) 
 
No differences were observed in 
those who underwent spontaneous 
remission (p = >0.05) 
Piotrowski 
et al 
(2012) (15) 
8-
isoprostane  
No healthy controls included; those with 
negative somatostatin scintigraphy scans 
were considered to have inactive 
sarcoidosis.  
8-isoprostane in those with a positive 
vs negative scintigraphy scans: 19.1 ± 
19.8 vs 5.4 ± 3.5pg/mL (p = 0.02) 
Not assessed or reported  Not assessed or reported  
 
Table 4: Results for studies evaluating markers of oxidative stress. Results presented as mean and standard deviation unless otherwise stated. Same key as per tables 1-3. 
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Author 
(year) 
Biomarker Differentiating Sarcoidosis from Healthy 
Controls 
(Sarcoidosis versus healthy controls) 
 
Differentiating Between Radiological 
Stage or Disease Activity 
  
 
Correlation with Pre-existing Clinical 
Biomarkers 
Effects with Respect to Treatment  
Piotrowski 
et al 
(2007) (16) 
8-isoprostane 
CysLT 
LTB4 
CysLT : 27.82 ± 6.65 vs 6.5 ± 0.0pg/mL;  p 
= <0.0001† 
 
LTB4: 23.14 ± 3.35 vs 20.09 ± 4.85pg/mL; 
p = 0.49† 
No significant difference reported 
according to clinical activity or 
radiological stage (p = >0.05). LTB4 
increased with radiological stage, 
however did not reach statistical 
significance (p = >0.05) 
 
No significant correlations reported in 
relation to DLCO (p = >0.05) 
Treatment naïve  
Corradi et 
al (2009) 
(22) 
Metallic 
elements:  
Aluminium  
Lead 
Nickel 
Chromium  
Silicon  
Cobalt  
Calcium  
Zinc  
Iron  
Copper  
Selenium  
Manganese  
Molybdenum 
Ni, Cr and Si were significantly higher in 
sarcoidosis compared to controls 
whereas Co, Zn, Se and Cu were all 
significantly lower in those with 
sarcoidosis (p<0.05). No significant 
difference was observed in Al, Pb, Ca, Fe, 
Mn and Mo between sarcoidosis and 
controls. Using multinomial logistic 
regression metallic patterns in EBC, 
including Cobalt (p=0.015), Nickel 
(p=0.002) and Selenium (p=0.043) could 
distinguish healthy controls from 
sarcoidosis, however overlap occurred in 
up to 63.6% of cases between 
sarcoidosis and other forms of ILD.  
No significant differences reported in 
relation to disease severity (p = >0.05) 
 
Iron concentration correlated 
positively with DLCO (r=0.46,p = <0.05) 
 
 
No significant differences reported 
in relation to treatment  
Piotrowski 
et al  
(2010c) 
(33) 
Hepatocyte 
growth factor 
40.9 ± 4.8 vs 52.1 ± 8.1pg/mL, p = >0.05† No significant differences reported 
according to clinical activity or 
radiological stage (p = >0.05) 
No significant correlations reported in 
relation to pulmonary function tests, 
BAL lymphocyte counts, ACE, CRP, 
calcium and 24 hour urinary calcium (p 
= >0.05) 
Treatment naïve 
Ahmadzai 
et al 
(2013) (23) 
Neopterin 
TGF-β1 
ACE 
Total protein  
Neopterin: 0.57 ± 0.45 vs 0.41 ± 
0.22nmol/L, p = 0.04 
 
TGF- β1: 115.5 ± 79.6 vs 82.3 ± 16.26pg 
mol-1, p = 0.048 
 
ACE detected in 2/16 sarcoidosis 
patients vs 3/20 controls, p = 0.91 
No significant difference reported 
according to radiological stage with 
neopterin (p = 0.76) or TGF- β1 (p = 
0.79) 
 
 
No significant correlations reported in 
relation to pulmonary function tests, 
however a general trend existed for 
both increasing neopterin (r2 = 0.36) 
and TGF- β1 (r2 = 0.297) with 
decreasing FEV1 
No significant differences reported 
in relation to treatment  
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Total protein: 17.8 ± 38.5 vs 8.1 ± 
2.3µg/mL, p = 0.27 
 
Loke et al 
(2015) (24) 
IL-27 1.8 ± 3.0pg/mL vs 3.1 ± 4.2pg/mL, p = 
0.57 
Not assessed or reported Not assessed or reported Not assessed or reported 
Mohan et 
al (2016) 
(7) 
TNFα 
Calcium 
Total protein  
TNFα: 3.37 ± 0.38 vs 2.59 ± 0.40pg/mL, p 
= 0.037† 
 
Calcium: 73.88 ± 13.35 vs 116.50 ± 
12.19µmol/L, p = 0.018† 
 
Total protein: 19.51 ± 4.52 vs 10.60 ± 
1.31µg/mL, p = 0.020† 
No significant difference reported 
according to radiological stage with 
either TNFα (p = 0.47), protein (p = 
0.36) or calcium (p = 0.17) 
No significant correlation reported in 
relation to serum calcium and EBC 
calcium (r=0.070, p = 0.81) 
 
Negative correlation was observed 
with EBC calcium concentration and 
FEV1 and FVC (r2= 0.32, p = 0.023 and 
r2=0.39, p = 0.009 respectively) 
Not assessed or reported, however 
authors stated that a patient with 
the most severe disease treated 
with inhaled, oral and intravenous 
steroids had undetectable TNFα 
 
Table 5: Results for studies evaluating cytokines, metallic elements and miscellaneous biomarkers. Results presented as mean and standard deviation unless otherwise stated. 
Same key as per tables 1-3; Ni, Nickel; Cr, Chromium; Si, Silicon; Co, Cobalt; Zn, Zinc; Cu, Copper; Se, Selenium; Al, Aluminium; Pb, Lead; Ca, Calcium; Fe, Iron; Mn, Manganese; 
Mo, Molybdenum.  
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Author 
(year) 
Nitric  Oxide 
Flow Rate  
Differentiating Sarcoidosis from 
Healthy Controls 
(Sarcoidosis versus healthy controls)  
 
Differentiating Between Disease Activity 
or Radiological Stage  
Correlation with Pre-existing Clinical 
Biomarkers 
Effects with Respect to Treatment  
O’Donnell 
et al 
(1997) (26) 
Peak, end-tidal 
and CALVNO 
7.8 ± 4.4 vs 7.1 ± 4.2ppb; p = 0.70 
 
 
No difference observed in peak, alveolar 
or end tidal nitric oxide when comparing 
hilar lymphadenopathy alone to 
interstitial infiltration on chest 
radiographs (p = 0.80, 0.44 and 0.46 
respectively)  
No significant correlation reported 
with serum ACE, BAL leucocyte counts 
or DLCO  
 
Treatment naïve  
Moodley 
et al 
(1999) (13) 
Alveolar  9.8 ± 0.4 vs 4.1 ± 0.2ppb; p = <0.001† Not reported  No significant correlation reported 
with serum ACE (r=0.13), FEV1(r=-
0.06), BAL CD4:CD8 ratio (r=0.07); (p = 
>0.05) 
Following 6 weeks treatment, 
nitric oxide fell from 9.8 ± 0.4 to 
5.9 ± 0.7ppb; p = 0.01 
 
 
Ziora et al 
(2004) (18) 
Mean end 
expiratory 
6.7 ± 0.50 vs 5.17 ± 0.73ppb, p = 
0.05† 
No difference reported according to 
disease activity (p = 0.43) or radiological 
stage when comparing stages I &II 
combined against stage III (p = 0.99) 
 
Nitric oxide correlated positively with 
DLCO (r=0.515,p = 0.029). No 
significant correlations reported 
between nitric oxide and FVC 
(r=0.163, p = 0.417), BAL lymphocyte 
counts (r=0.180, p = 0.449)  
 
No significant differences 
identified between those with and 
without indications for 
commencing treatment (p = 0.124)  
 
 
Wilsher et 
al (2005) 
(25) 
 
Plateau of end 
expiration 
when carbon 
dioxide 70-80% 
of maximum 
 
Median 6.8ppb (range 2.4-21.8 ) vs 
6.3ppb (1.6-28.0); (p-value not 
reported) 
 
No significant differences reported 
according to disease severity as assessed 
upon HRCT CT scoring;  (p-value not 
reported) 
 
No significant correlation reported in 
relation to pulmonary function tests; 
(p-value not reported) 
 
Treatment free at enrolment 
Choi et al 
(2009) (14) 
Various flow 
rates, CALVNO, 
JAWNO 
Active sarcoidosis: 3.8 ± 3.3 vs 4.7 ± 
3.0ppb; p = >0.05 
 
Inactive sarcoidosis: 5.7 ± 4.2 vs 4.7 ± 
3.0ppb; p = >0.05 
 
 
 
 
 
 
No significant differences reported with 
any flow rate of exhaled nitric oxide, 
CALVNO or JAWNO in relation to clinical 
activity or radiological stage.  
CALVNO correlated negatively with FVC 
(r=-0.52,p = 0.001) and DLCO (r=-0.40, 
p = 0.012). No significant correlations 
reported in relation to ACE.  
 
No consistent differences observed 
in nitric oxide in relation to 
treatment at follow-up.  
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Cameli et 
al (2016) 
(19) 
Various flow 
rates, CALVNO 
6.0 ± 3.1 vs 4.7 ± 2.3ppb; p = >0.05.  
 
 
No significant differences reported 
according to radiological stage; (p-value 
not reported)  
Not assessed or reported No significant differences reported 
in relation to steroid treatment  
 
Table 6: Results for studies evaluating exhaled nitric oxide. Where exhaled nitric oxide was measured and reported at various flow rates including calculation of CALVNO and 
JAWNO, only alveolar nitric oxide has been tabulated in the above result table when comparing participants with sarcoidosis to healthy controls. No significant differences were 
observed for nitric oxide at any other flow rates in the studies. Results presented as mean and standard deviation unless otherwise stated. Same key as per tables 1-3. 
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Author 
(year) 
Differentiating Sarcoidosis from Healthy Controls 
(Sarcoidosis versus healthy controls) 
 
Differentiating Between Radiological 
Stage or Disease Activity 
 
Correlation with Pre-existing Clinical 
Biomarkers 
Effects with Respect to Treatment 
Mazzone 
et al 
(2007) (32) 
Sarcoidosis vs all other groups: model error rate 
10%, validation sensitivity 16.7% and specificity 
81.1%, p = 0.69 
 
Not assessed or reported Not assessed or reported Not assessed or reported  
Westhoff 
et al 
(2007) (29) 
Across all chromatograms, thirteen peaks were 
identified for discrimination, six of which appeared 
to be specific for a participant with sarcoidosis. 
Principle component analysis allowed separation 
of those with confirmed sarcoidosis compared to 
those who received a negative diagnosis.  
Not assessed or reported  Not assessed or reported Not assessed or reported 
Dragonieri 
et al 
(2013) (30) 
VOC profiles discriminated untreated pulmonary 
sarcoidosis from healthy controls with a cross 
validated accuracy (CVA) of 83.3% (p = <0.001).  
 
Not assessed or reported Not assessed or reported Untreated and treated sarcoidosis 
could be less well discriminated 
against (CVA 74.2%). Breath prints 
were undistinguishable between 
treated sarcoidosis and controls (CVA 
66.7%) 
 
Fijten et al 
(2017) (31) 
430 different VOCs identified across the samples; 
9 VOCs in the discovery study were discriminatory 
(Isoprene, 2-methylpentane, benzene, 3-
methylhexane, p-Benzoquinone, phenol, D-
limonene, iodomethylcyclopentane and 
dibenzofuran) which could predict sarcoidosis with 
79.4% accuracy (sensitivity and specificity 75.4% 
and 92.5% respectively).  
 
During the validation study overall prediction rate 
was 74.1% accurate (sensitivity and specificity 68% 
and 79.3% respectively).  
Not assessed or reported Not assessed or reported Not assessed or reported 
Table 7: Results for studies evaluating volatile organic compounds.  
Same key as per tables 1-3.  
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Figure 3: QUADAS-2 assessment  
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Figure 4: QUADAS-2 assessment  
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